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AbsTrACT
Objectives Online testing for Stis might complement 
regular care provided by general practitioners or Sti 
clinics. two types of online testing can be distinguished, 
self-testing and self-sampling (sending sample to a 
laboratory for diagnosis). Online testing can occur 
without consultation with a healthcare professional, 
therefore information given by providers is essential 
for informed decision-making. We aimed to enumerate 
online test providers in the netherlands focusing on 
chlamydia tests, to evaluate information using quality 
indicators and to gain insight on the proportion of online 
testing in the Sti testing arena.
Methods We performed a systematic internet search 
to identify online Sti test providers. twenty quality 
indicators were evaluated on their websites; indicator 
scores were weighted by level of importance (expert 
opinion). High scoring providers were recommended, on 
the condition that the sensitivity and specificity of the 
test were above 95% and providers included a follow-up 
procedure in case of a positive result. Finally, providers 
were contacted to inquire about the number of sold 
tests, positivity rates and demographic characteristics of 
testers.
results Five out of 12 identified self-sample test 
providers could be recommended, versus zero out of 
eight self-test providers. Self-sample test providers gave 
complete and correct information on more indicators 
(67%) compared with self-test providers (38%). in 
2015, an estimated 30 000–40 000 self-sample tests 
were purchased, and 12 000–25 000 self-tests, which is 
roughly 10%–15% of the total number of Sti tests.
Conclusion this evaluation shows that some online 
self-sample test providers could be put forward as way of 
Sti testing complementing regular testing options. none 
of the self-test providers were recommended. regularly 
evaluating online test providers is advised to improve 
quality of the information on the websites. Finally, self-
testing might not be suited for all populations as most 
information is provided in written format only.
InTrOduCTIOn
Worldwide, Chlamydia trachomatis (Chlamydia) 
remains the most prevalent bacterial STI, with 
yearly increasing number of cases diagnosed in 
the Netherlands.1 Chlamydia infections are associ-
ated with severe reproductive complications, such 
as pelvic inflammatory disease, ectopic pregnancy 
and tubal subfertility,2–4 thus chlamydia control 
is of public health importance. Previously, chla-
mydia control through testing in the Netherlands 
was mainly the responsibility of general practi-
tioners (GP) or in dedicated STI clinics. However, 
recently STI clinics have had a hard time coping 
with increasing demands for testing,1 and STI and 
sexuality are still sensitive subjects keeping certain 
groups of people from visiting the GP.5–7 Therefore, 
more and more people are searching for alterna-
tives. As such, online STI testing offers an anony-
mous testing opportunity that might appeal to those 
not able or willing to test at the GP or STI clinic.
Indeed, the number of web shops offering online 
testing for almost every STI has increased over the 
past few years in the Netherlands.8 9 Unfortunately, 
information on the number of people using online 
STI testing is scarce. One study with an internet 
panel performed in 2006 reported that 1.4% of 
their sample had used a chlamydia self-test,10 a few 
years later in 2008 1.6% had used a chlamydia self-
test.11 Another study similarly showed that among 
young people in Amsterdam 1.0% had used a self-
test for STI or HIV.12 In the UK, researchers found 
comparable numbers, with 1.8% of respondents 
reporting the use of a chlamydia self-test in the 
last year.13 Among people who are testing for STI 
(instead among people who might not have tested 
for STI at all), a recent study in England reported 
that 10% of the total proportion of testing was 
done with online tests.14
Online testing can be done without consultation 
with a healthcare professional. This means that these 
online tests often are not part of routine surveil-
lance, and it is not mandatory to follow the same 
procedure as GPs and healthcare professionals in 
STI clinics. Also, people who might want to buy an 
online test need information on, for instance, which 
STI to test for (tests that are offered include chla-
mydia, gonorrhoea, syphilis, hepatitis B, HIV, trich-
omonas, candida), which locations to test (genital, 
anal or oral) and when to test (window phase). 
Furthermore, after testing ultimately people should 
receive information on, for instance, risk preven-
tion, partner notification and treatment. Therefore, 
it is crucial to gain insight into the quality of infor-
mation supplied by online test providers.
The information people require might differ 
depending on the type of test they are considering. 
There are two types of online tests offered: self-
sample tests and self-tests.15 Self-sample tests are 
copyright.
 on A














381den Daas C, et al. Sex Transm Infect 2019;95:380–385. doi:10.1136/sextrans-2018-053771
Epidemiology
sampling kits used at home (or any other suitable place) for 
self-collection of urine, blood or other material by swab. These 
samples are sent to a laboratory where diagnosis takes place, 
similar laboratory methods are used as at GPs or STI clinics. 
People receive the result (ie, with a code online, via email or 
telephone), which also provides the opportunity to link people 
to follow-up procedures, such as post-test counselling and, in 
case of a positive diagnosis, a referral to a GP and partner noti-
fication. Self-tests are performed at home (or any other suitable 
place); and the diagnosis is obtained there. The self-testing kit 
shows the diagnosis using symbols or coloration (comparable to 
pregnancy tests). Therefore, in contrast to self-sample test where 
the diagnosis is communicated, for self-tests at no point in the 
procedure people need to have direct contact with a healthcare 
professional, making the information provided on the website 
even more essential. Furthermore, most self-tests for chlamydia 
and other STI have a low sensitivity and are therefore not ready 
for widespread use.16 For lay people however, the disadvantage 
of having a test with low sensitivity is not common knowledge, 
which means they might unknowingly choose an unreliable test 
based on the information of the website.
In the present study, we will enumerate the online test 
providers in the Netherlands. Furthermore, their websites will 
be systematically assessed and evaluated based on quality indi-
cator criteria, resulting in recommended providers and a quality 
standard for information of online provided STI testing. The 
quality indicators used will be based on previous report of STI 
Aids Netherlands published in 2011 and 2013, in which they 
made an overview of Dutch providers of online tests.8 9 Finally, 
we aimed to explore the proportion of STI testing that is done 
via online testing in the Netherlands, by contacting all providers 
and inquire about the number of tests sold within a year, posi-
tivity rate and customer demographic characteristics.
METhOds
Inclusion self-test providers
The self-test providers were identified using the most used search 
engine (Google). Dutch terms such as ‘SOA zelf-test (STI self-
test)’, ‘SOA test (STI test)’, ‘SOA lab-test (STI lab-test)’, ‘thuis-
test (home-test)’ and ‘testen op SOA’ (test for STI) were used 
to find providers. Additionally, providers mentioned in previous 
reports of STI Aids Netherlands were included.8 9 Providers just 
reselling self-tests such as  Bol. com,  Amazon. de,  drogisterij. net, 
thuistesters. nl and Google Shopping were not included, but also 
used to identify providers. Inclusion criteria were: usage of a 
Dutch web address and product available in the Netherlands.
Indicator criteria
The information on the websites of the self-test providers on 
1 February 2016 was evaluated. First, we described the self-
test providers with six characteristics, such as type of self-test, 
price and type of sampling (data not shown). Then we evaluated 
the information using 20 quality indicators, an overview of the 
indicators is shown in table 1. The indicators used in the 2011 
and 2013 reports from STI Aids Netherlands8 9 were updated 
in collaboration with experts from STI Aids Netherlands and 
the STI Department of the National Institute of Health and 
the Environment (RIVM). Each quality indicator could score 
between 0 and 1. This score was weighted (weights provided in 
table 1) based on importance as indicated by the experts from 
the STI Department of RIVM and STI Aids Netherlands.
The evaluation was implemented for chlamydia tests or, if 
not applicable, the information for HIV or syphilis tests was 
assessed. The maximum score for self-sample test providers was 
45 points, and for self-test providers was 42 points, two quality 
indicators were only applicable for self-sample test providers. 
Providers who scored two-thirds or higher on the evaluation 
were deemed satisfactory (30 and 28 points, respectively). Self-
sample test providers or self-test providers who scored nine-
tenths or higher (40 and 37 points, respectively) were highly 
recommended. This positive evaluation was dependent on two 
conditions: (1) the test had to have a sensitivity and specificity 
of 95% or higher, and (2) in case of a positive diagnosis active 
follow-up is provided. If one of these conditions was not met, 
providers could not be recommended, irrespective of the height 
of their score.
Provider contact
We attempted to contact all providers by telephone or email to 
estimate the proportion of testing done via online providers in 
Dutch STI testing in 2015. They were asked to provide informa-
tion on (a range of) the number of tests sold, positivity rate and 
customer demographic characteristics. As this is company infor-
mation, we only present information on an aggregated level. We 
will compare the number of tests sold with the number of tests 
done via GPs and STI clinics.1
statistical analysis
We calculated total weighed scores for all providers. Subse-
quently, we calculated the percentage the provider obtained out 
of the total score that could be obtained, and compared these 
for both types of test providers using an independent samples 
t-test with p<0.05 reflecting a statistical significant outcome. In 
addition, we performed Pearson’s χ2 test to compare the scores 
on each of the quality indicators separately.
rEsulTs
Providers
We identified 20 websites selling tests (12 self-sample test 
providers and eight self-test providers). Prices for self-sample 
tests (mean=€47.42, SD=€17.04) ranged from €33 for a chla-
mydia test up to €63 for a gonorrhoea and chlamydia combina-
tion test. One of the self-sample tests could be ordered for free 
as this provider is linked to STI clinics. Self-tests (mean=€21.88, 
SD=€6.92) were available from €15 up to €30 for a chlamydia 
test.
Quality indicators
Self-sample test providers scored between 10.8 and 43 points, 
and 6 out of 12 (50%) scored satisfactory. However, one of 
these providers did not mention the follow-up procedure, and 
was therefore not recommended. Two out of 12 (16.6%) self-
sample test providers were highly recommended. All self-sample 
test providers reported sensitivity and specificity of above 95%, 
4 out of 5 (80%) recommended providers indicated to use a 
nucleic acid amplification test (NAAT) and one of the recom-
mended providers did not provide this information.
Self-test providers scored between 5.5 and 29.3 points. 
Reported sensitivity and specificity ranged from 85% to 99.9%. 
However, none of the self-test providers reported both sensi-
tivity and specificity above 95%, therefore none could be 
recommended. Self-test providers (mean=38.0, SD=18.2) 
scored significantly lower on average on the quality indica-
tors compared with self-sample test providers (mean=66.8, 
SD=19.7), t (18)=3.30, p<0.01. Self-sample test providers 
were more thorough in their information provision; self-sample 
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Table 1 The 20 quality indicators used to rate information provided by STI self-test and self-sample test providers on their websites, the used 
weigh factors, scoring and additional comments
Indicator Explanation Weight scoring notes 
decision making
Anal/oral testing Does the provider describe:
1. Possibility of anal/oral infections
2. Advise on anal/oral sampling
4 Good=both (+1)
Moderate=1 or 2 (+0.5)
Poor=0 (+0)
Providers selling tests 
including specific kits 
for anal or oral sampling 
automatically score ‘Good’
STI comorbidity Does the provider mention that it is possible to acquire more than one kind of STI 
during intercourse and that it therefore would be advised to test for more than one 
STI?
3 Yes (+1) No (+0)
Basic STI 
information
Basic information about the concerned STI described:
1. Symptoms
2. Incubation time (window phase)
3. Transmission route
4. Type of sample (blood, urine or swab)
5. Risk factors
6. Ways of treatment
7. Easy to find on website, discussed in separate section
3 Good=All 7 (+1)
Sufficient=6 or 5 (+0.75)
Moderate=4 or 3 (+0.5)
Insufficient=2 or 1 (+0.25)
Poor=0 (+0)
Window phase 1. Definition is explained (time between getting infected and moment the infection 
can be detected by a test)




Incubation time (time 
between infection and 
symptoms) scores moderate
Testing tool Decision tool used for triage, what self-test(s) should be bought, based on gender, 
sexual preferences and sexual activity
2 Yes (+1) No (+0)
Risk prevention Basic information about prevention of STI described:
1. Condom use during vaginal, oral and anal intercourse
2. Avoid sharing potentially infected/dirty (drug) needles
3. Tips for successful condom use
4. Condom use is advised (based on sex behaviour)
5. Condoms can be bought on website or link to condom shop
6. Easy to find on website, discussed in separate section
2 Good=all 6 (+1)
Sufficient=5 or 4 (+0.75)
Moderate=3 (+0.5)
Insufficient=1 or 2 (+0.25)
Poor=0 (+0)
reliability
Level The test has a sensitivity+specificity of 95% or higher 4 Yes (+1) No (+0)
Described Does the provider describe the sensitivity and specificity of the test and are these 
numbers explained in a clear way that ignorant customers can understand what 
these numbers mean?
2 Yes (+1) No (+0)
Support Does the provider provide literature on the website, which describes/supports the 
sensitivity and specificity?
2 Yes (+1) No (+0)
Quality marks for 
laboratory
Does the provider describe what marks/labels apply for their laboratory (performing 
the diagnose)?
1 Yes (+1) No (+0) Only self-sample test 
providers
Quality marks for 
testing kit




Possibility to call or mail a healthcare professional for questions prior to testing 2 Yes (+1) No (+0)
Video instructions Is there a video which shows how the sample kit works and what procedures are 
needed to gather a sample?
1 Yes (+1) No (+0)
Dutch instructions Is there a Dutch leaflet and Dutch text on packaging? 1 Yes (+1) No (+0) Either be mentioned or 
derived from pictures on the 
website
Contact provider Possibility to call or mail the provider for further questions 1 Yes (+1) No (+0)
Diagnostic 
technique
Is the type of test (NAAT or antibody) indicated on the website? 1 Yes (+1) No (+0)
Follow-up
Follow-up What follow-up procedure after receiving result is applied?
1. Partner notification can be performed through provider (P)
2. Ways of treatment explained, instruction given what to do next and how to get 
treatment (T)
3. Counselling by health professional possible after receiving positive result (C)






Referral to GP Does the provider advise to visit a general practitioner (GP), hospital, nurse, STI 
clinic or any other professional healthcare worker/institute when the test result is 
positive?




 ► Active (telephone=T, SMS=M or mail=E)
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Indicator Explanation Weight scoring notes 
Partner notification Does the provider mention that partner notification is important in case of positive 
result?
2 Yes (+1) No (+0)
NAAT, nucleic acid amplification test; SMS, short message service.
Table 1 Continued
Table 2 Results of the evaluation of the self-test and self-sample test 
providers, showing the number of providers scoring positive (answer 




providers (n=8) χ2 outcome
n % n %
Anal/oral testing 
(Good)
7 58.3 0 0.0 Χ2 (1)=7.18, 
p<0.01
STI comorbidity (Yes) 10 83.3 4 50.0 Χ2 (1)=2.54, 
p=0.11
Basic STI information 
(Good)
6 50.0 4 50.0 Χ2 (1)=0.00, 
p=1.00
Window phase (Good) 7 58.3 1 12.5 Χ2 (1)=4.20, 
p=0.04
Testing tool (Yes) 7 58.3 0 0.0 Χ2 (1)=7.18, 
p<0.01
Risk prevention (Good) 1 8.3 0 0.0 Χ2 (1)=0.70, 
p=0.40
Reliability level (Yes) 12 100.0 0 0.0 Χ2 (1)=20.00, 
p<0.01
Reliability described 3 25.0 3 37.5 Χ2 (1)=0.36, 
p=0.55
Reliability supported 1 8.3 1 12.5 Χ2 (1)=0.09, 
p=0.76
Quality marks for 
laboratory (Yes)
10 83.3 – – –
Quality marks for 
testing kit (Yes)












12 100.0 7 87.5 Χ2 (1)=1.58, 
p=0.21
Contact provider (Yes) 12 100.0 8 100.0 –
Diagnose technique 
(Yes)
7 58.3 6 75.0 Χ2 (1)=0.59, 
p=0.44
Follow-up (2 or more) 5 41.6 0 0.0 Χ2 (1)=4.44, 
p<0.04
Referral to general 
practitioner (Yes)




7 58.3 – – –
Partner notification 
(Yes)
10 83.3 4 50.0 Χ2 (1)=2.54, 
p<0.11
Bold printed statistics differ, p-values < .05 are considered significant.
test providers gave more correct and good information on the 
quality indicators in comparison to the self-test providers (see 
table 2 for comparisons per indicator). Notably, the self-sample 
test providers who were highly recommended satisfied almost all 
quality indicators.
Provider information
We were able to contact all 12 self-sample test providers through 
email or telephone. The estimated total number of self-sample 
tests sold in the previous year ranged from 30.000 to 40.000. 
Positivity rates ranged from 3% up to 18%. The average 
customer is aged between 18 and 35 years, mostly heterosexual 
and more often male than female, according to the providers. 
Four of the self-test providers were reached by telephone or 
email. These providers sold an estimated 12.000–25.000 self-
tests in the previous year. Only one provider gave informa-
tion on positivity rates, and one provider gave information on 
customer demographic characteristics, therefore this informa-
tion is not discussed any further. In total, 42.000–65.000 online 
tests were sold in 2015. Roughly estimated 10%–15% of chla-
mydia testing in the Netherlands takes place using self-tests or 
self-sample tests.
dIsCussIOn
We identified and evaluated 20 online STI test providers using 
20 quality indicators. Five out of 12 self-sample test providers 
scored satisfactory and met the two conditions of reliable testing 
(sensitivity and specificity above 95%) and active follow-up in 
case of a positive diagnosis. None of the eight self-test providers 
met these conditions. Notably, besides the reliability of the tests, 
there was also a big difference between self-sample test providers 
and self-test providers on the quality of their information. Most 
providers could improve the information on their websites to 
help people make an informed and correct choice for an STI 
test and how to proceed after purchase, but most self-sample 
test providers gave more and more correct information than the 
providers of self-tests.
Interestingly, while performing this evaluation many of the 
providers (especially those who were already positively evalu-
ated in our assessment) used the quality criteria to improve their 
website. Consequently, soon after this evaluation, the informa-
tion given on some of the websites was more complete. This is 
indicative of the concern certain providers have about the quality 
of their services and the well-being of people purchasing tests.
A strength of this study is that besides knowing how many 
providers there are in the Dutch online testing market, for the 
first time we also have an estimation of the proportion of tests 
that self-testing and self-sampling via online providers hold in 
relation to testing of chlamydia via GPs and STI clinics in the 
Netherlands. The number of STI consults of the STI clinics and 
GP was approximately 400.000 in 2015 in the Netherlands. Based 
on the raw data we received of the online providers (42.000–
65.000 tests sold in the previous year), roughly 10%– 15% of 
chlamydia testing takes place using self-tests or self-sample tests. 
On the one hand, this number could be an overestimation, as it 
is unclear whether people who bought an online self-test also 
used it (and even more unclear is whether it was used correctly).
On the other hand, the estimate might be an underestima-
tion, as we did not include physical stores or resellers that sell 
STI tests in our evaluation. Importantly, resellers usually do not 
give any or very little information, and would therefore not 
be recommended in this evaluation. Physical stores usually sell 
self-test of undetermined reliability, which also could result in 
suboptimal choices and a possible problem in management of 
chlamydia transmission. There is uncertainty in the estimated 
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number of tests, the providers gave a range, some providers 
were not reached and new providers start offering self-tests and 
self-sample test; therefore, these numbers should be used as an 
indication and should be interpreted with caution. More exact 
figures into how many people are self-testing, and who they are, 
would be ideal, but will be hard to obtain due to the anony-
mous character of online testing and the commercial interest of 
online test providers. However, recent data from England also 
indicated 10% of tests were online tests,14 providing some vali-
dation of the numbers in this study.
A limitation is that we evaluated the information on commer-
cial websites, which may provide biased information. One quality 
indicator that might particularly be affected is the reported 
sensitivity and specificity. We have not verified the claims, and 
only few providers presented literature to support the reported 
sensitivity and specificity. We chose a sensitivity and specificity 
of above 95% as acceptable, as there is no golden standard. Even 
with optimistic reporting, none of the self-test providers satisfied 
this criterion. Of the self-sampling test providers, all reported 
to satisfy this criterion, and most of the recommended test 
providers indicated to use NAAT tests including the name of a 
laboratory. Therefore, most likely these self-sample tests indeed 
were reliable (even beyond the >95% sensitivity and specificity). 
Future studies might aim at in-depth investigation to verify these 
claims.
The fast-changing and dynamic market is reflected in the 
increase in self-test providers from 6 to 8 since the last report 
from STI Aids Netherlands in 2013.8 Two self-sample test 
providers examined in 2013 did not exist anymore, however 
four new providers filled the gap. Furthermore, four self-test 
providers no longer existed, while four new providers were 
found. Providers and information can change from 1 day to the 
next. This is positive as evaluations like the one in the current 
study directly improve quality of the information provided, but 
it also complicates keeping the overview. For one ‘new’ provider 
we know it was the same provider under a different name, for 
the others this possibility cannot be excluded. Changing names 
is a known phenomenon in self-test providers,17 when, for 
example, there is too much scrutiny on their unsubstantiated 
claims of test quality.
Apart from data from one self-sampling provider, online 
testing is currently not included in routine surveillance, which 
means the number of people who are testing is underestimated, 
approximately by 10%–15%, and the number of reported cases 
is incomplete. For now, it is unclear whether online test providers 
are reaching a different audience. Possibly people who experi-
ence more barriers might be testing online, this means positivity 
rates might be higher. It could also be an easier opportunity 
for the ‘worried-well’ to test, leading to lower positivity rates. 
Surveillance data on the total number of tests might become 
available—with effort—, but complete information on positivity 
rates cannot be obtained, and would not be meaningful as there 
are no reliable self-tests (yet).16 18
A clear implication is that the development of a reliable 
self-test for chlamydia is essential to improve the added value 
of online testing. It is also essential to gain insight into the 
follow-up of positive cases; although chlamydia is easy to treat 
(single dose), prescriptions are required. While doing this evalu-
ation we noticed that when searching for self-test, the results of 
self-test providers (not self-sample providers) are usually shown 
at the top of the page in the advertised links. This means that 
people without much knowledge might be enticed to choose a 
self-test above a self-sample test, which is not warranted by their 
quality just yet.
A final implication of this research is that we should work 
towards more information on who is testing online. Our 20 indi-
cators already show that to make the best (or even an acceptable) 
decision people should incorporate a lot of information. Also, 
most information provided on the websites is in written format. 
This means this way of testing is probably not well suited for the 
most vulnerable populations (ie, people with lower education, 
people with a migration background or people with low (health) 
literacy).
COnClusIOn
Internet is an intrinsic part of everyday life; therefore, the 
trend in online testing of STI is likely to keep increasing in the 
upcoming years. In theory, self-sample tests can be a valuable 
complement to standard care provided by GPs and STI clinics, 
as they can be cheap, easy, reliable (for now just the self-sample 
tests) and anonymous. Taking into account that several self-
sample test providers provide good quality information to assist 
people to make well-informed choices, this evaluation shows 
that self-sample tests could potentially be put forward as an addi-
tional test possibility. However, none of the self-test providers 
could be recommended. Our evaluation shows that regular eval-
uations are advisable to improve quality of information on the 
websites and that without official accreditation the quality of 
online testing cannot be guaranteed. Without these, it is diffi-
cult for users of self-tests to know which providers do provide 
quality services. This evaluation additionally shows that online 
testing might not be suited for all populations given the emphasis 
on written information.
Key messages
 ► The known increase in providers offering online STI testing 
persisted in this study, with an increase of two providers in 
3 years.
 ► Five out of 12 self-sample test providers could be 
recommended, self-sample test providers give better 
and more complete information compared with self-test 
providers.
 ► Roughly estimated, self-testing represents 10%–15% of 
chlamydia testing in the Netherlands in 2015, which is much 
higher than previous studies showed.
 ► Improving data collection on user characteristics and 
positivity rates for surveillance is difficult, especially as there 
are no reliable chlamydia self-tests yet.
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